Sign in

    Steven S. Williamson

    President and CEO at Pulmonx Corp
    Since March 15, 2024
    Age
    51 years
    Education
    Earned a Bachelor of Business Administration from the University of Massachusetts, Amherst and a Master of Business Administration from Bentley College.
    Tenure
    Appointed as President and CEO on March 15, 2024, and also serves as a Class II member of the Board of Directors at LUNG.

    Also at Pulmonx Corp

    DL
    David Lehman
    General Counsel
    GBR
    Geoffrey Beran Rose
    Chief Commercial Officer
    JM
    John McKune
    Vice President, Corporate Controller

    About

    Steven S. Williamson is the current President and Chief Executive Officer of Pulmonx Corporation (LUNG). He assumed this role on March 15, 2024, following a successful career in the medical device industry.

    Before joining LUNG, he built nearly 30 years of experience through several high-profile leadership roles, including serving as Chief Commercial Officer at Outset Medical, Inc. from November 2020 to February 2024, as well as holding pivotal positions at C.R. Bard/Becton, Dickinson and Company and Hologic, Inc..

    Under his leadership at LUNG, the company has focused on expanding patient access to innovative therapies, achieving record financial results in 2024 with $83.8 million in worldwide revenue, a 22% year-over-year increase, and a 74% gross margin. His strategic direction emphasizes commercial excellence, innovative product launches, and transformative market growth.

    In addition to his considerable professional accomplishments, his academic foundation, including a Bachelor of Business Administration from the University of Massachusetts, Amherst and an MBA from Bentley College, has played a key role in his strategic approach to leadership.

    $LUNG Performance Under Steven S. Williamson

    Past Roles

    OrganizationRoleDate RangeDetails
    C.R. Bard / Becton, Dickinson and Company (BD) Worldwide President for the Peripheral Intervention business unit August 2012 to November 2020 (last role ended in October 2020) Held various roles culminating in this executive position; last role ended in October 2020
    Novacept Inc. Employee May 2003 to August 2012 Acquired by Cytyc Corporation in March 2004
    Cytyc Corporation / Hologic, Inc. Senior Vice President and General Manager of the GYN Surgical Products Business Approximately March 2004 to October 2007 Held various roles with increasing responsibility through the acquisition by Hologic, Inc.

    Fixed Compensation

    Data from  FY 2024
    Component NameAmountPayment ScheduleAdditional Details
    Annual Base Salary$580,000 Payable in two equal payments per month Subject to annual review by the Board
    Reimbursement for Commuting ExpensesReimbursed N/ACovers travel and California lodging/housing expenses, including a tax gross-up

    Performance Compensation

    Data from  FY 2024

    No information available on performance compensation for 2024